DNLI
Price
$23.31
Change
+$0.27 (+1.17%)
Updated
Jan 22 closing price
Capitalization
3.35B
39 days until earnings call
NAUT
Price
$2.00
Change
-$0.01 (-0.50%)
Updated
Jan 23, 10:30 AM (EDT)
Capitalization
252.38M
28 days until earnings call
Ad is loading...

DNLI vs NAUT

Header iconDNLI vs NAUT Comparison
Open Charts DNLI vs NAUTBanner chart's image
Denali Therapeutics
Price$23.31
Change+$0.27 (+1.17%)
Volume$1.03M
Capitalization3.35B
Nautilus Biotechnolgy
Price$2.00
Change-$0.01 (-0.50%)
Volume$444
Capitalization252.38M
DNLI vs NAUT Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. NAUT commentary
Jan 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and NAUT is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 23, 2025
Stock price -- (DNLI: $23.31 vs. NAUT: $2.01)
Brand notoriety: DNLI and NAUT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 102% vs. NAUT: 76%
Market capitalization -- DNLI: $3.35B vs. NAUT: $252.38M
DNLI [@Biotechnology] is valued at $3.35B. NAUT’s [@Biotechnology] market capitalization is $252.38M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.37B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileNAUT’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • NAUT’s FA Score: 1 green, 4 red.
According to our system of comparison, NAUT is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while NAUT’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 2 bearish.
  • NAUT’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, both DNLI and NAUT are a good buy in the short-term.

Price Growth

DNLI (@Biotechnology) experienced а +8.42% price change this week, while NAUT (@Biotechnology) price change was +3.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.70%. For the same industry, the average monthly price growth was +2.32%, and the average quarterly price growth was -2.48%.

Reported Earning Dates

DNLI is expected to report earnings on May 13, 2025.

NAUT is expected to report earnings on May 06, 2025.

Industries' Descriptions

@Biotechnology (+1.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($3.36B) has a higher market cap than NAUT($252M). NAUT YTD gains are higher at: 19.643 vs. DNLI (14.377). NAUT has higher annual earnings (EBITDA): -75.11M vs. DNLI (-496.05M). DNLI has more cash in the bank: 837M vs. NAUT (141M). NAUT has less debt than DNLI: NAUT (31.6M) vs DNLI (52.5M). DNLI (0) and NAUT (0) have equivalent revenues.
DNLINAUTDNLI / NAUT
Capitalization3.36B252M1,331%
EBITDA-496.05M-75.11M660%
Gain YTD14.37719.64373%
P/E RatioN/AN/A-
Revenue00-
Total Cash837M141M594%
Total Debt52.5M31.6M166%
FUNDAMENTALS RATINGS
DNLI vs NAUT: Fundamental Ratings
DNLI
NAUT
OUTLOOK RATING
1..100
195
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
21
Undervalued
PROFIT vs RISK RATING
1..100
91100
SMR RATING
1..100
9595
PRICE GROWTH RATING
1..100
5062
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/a75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NAUT's Valuation (21) in the null industry is significantly better than the same rating for DNLI (94) in the Biotechnology industry. This means that NAUT’s stock grew significantly faster than DNLI’s over the last 12 months.

DNLI's Profit vs Risk Rating (91) in the Biotechnology industry is in the same range as NAUT (100) in the null industry. This means that DNLI’s stock grew similarly to NAUT’s over the last 12 months.

DNLI's SMR Rating (95) in the Biotechnology industry is in the same range as NAUT (95) in the null industry. This means that DNLI’s stock grew similarly to NAUT’s over the last 12 months.

DNLI's Price Growth Rating (50) in the Biotechnology industry is in the same range as NAUT (62) in the null industry. This means that DNLI’s stock grew similarly to NAUT’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as NAUT (100) in the null industry. This means that DNLI’s stock grew similarly to NAUT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLINAUT
RSI
ODDS (%)
Bullish Trend 16 days ago
90%
Bullish Trend 16 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 16 days ago
81%
Bullish Trend 16 days ago
82%
Momentum
ODDS (%)
Bullish Trend 16 days ago
80%
Bullish Trend 16 days ago
81%
MACD
ODDS (%)
Bullish Trend 16 days ago
79%
Bullish Trend 16 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 16 days ago
81%
Bullish Trend 16 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 16 days ago
85%
Bearish Trend 16 days ago
79%
Advances
ODDS (%)
Bullish Trend 16 days ago
79%
Bullish Trend 22 days ago
81%
Declines
ODDS (%)
Bearish Trend 25 days ago
78%
Bearish Trend 25 days ago
81%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 16 days ago
83%
Bearish Trend 16 days ago
79%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NAUT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FNPFX64.680.34
+0.53%
American Funds New Perspective F3
PWETX13.290.01
+0.08%
PACE International Em Mkts Eq P2
GPIGX13.44N/A
+0.01%
Guidepath® Growth and Income
MDFGX38.02N/A
N/A
BlackRock Capital Appreciation Inv A
FAIRX31.13-0.26
-0.83%
Fairholme

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+1.17%
BEAM - DNLI
60%
Loosely correlated
+7.58%
LGND - DNLI
54%
Loosely correlated
-1.28%
PRTA - DNLI
51%
Loosely correlated
+2.27%
NTLA - DNLI
51%
Loosely correlated
+10.76%
CDXS - DNLI
51%
Loosely correlated
-3.56%
More

NAUT and

Correlation & Price change

A.I.dvisor indicates that over the last year, NAUT has been loosely correlated with PLRX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NAUT jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NAUT
1D Price
Change %
NAUT100%
-1.47%
PLRX - NAUT
45%
Loosely correlated
-1.36%
AURA - NAUT
43%
Loosely correlated
N/A
DNLI - NAUT
43%
Loosely correlated
+1.17%
PRTA - NAUT
43%
Loosely correlated
+2.27%
AXON - NAUT
42%
Loosely correlated
+0.33%
More